<\/p>\n
Shoppers of disclosure language are rewriting their playbooks: funds, operators and advisers need new risk factors and valuation work after the DOJ\/DEA Final Order moved certain medical cannabis into Schedule III. This matters for S\u20111s, PPMs, M&A diligence and tax models , and the window to update is now.<\/strong><\/p>\n Essential Takeaways<\/p>\n The Final Order effective 22 April 2026 creates a practical bifurcation of federal risk that every disclosure package must reflect, and it does so with a sensory jolt , imagine investors suddenly smelling the possibility of real cash\u2011flow upside where once there was only smoke. Previously, disclosure was built around uniform federal illegality and the certainty of 280E\u2019s bite. Now, state\u2011medical\u2011licensed activity sits in a different lane. That forces mechanical edits to boilerplate risk factors and substantive recalibration of tax models, valuation caps and covenant assumptions.<\/p>\n According to the Treasury press release and firm alerts, guidance from Treasury, IRS and FinCEN is expected to follow, and those future rules will determine who benefits and to what degree. So counsel and finance teams should be rewriting language now while also flagging contingent language about guidance, litigation and allocation methods.<\/p>\n The foundational rewrite is simple: stop saying cannabis is unequivocally Schedule I without qualification. Disclosure must explain that while cannabis is generally Schedule I, FDA\u2011approved products and qualifying state\u2011licensed medical activity are treated as Schedule III where applicable. That pivot changes every downstream risk statement , from 280E to DEA registration , and it invites new items, like litigation risk to the Final Order itself.<\/p>\n Practical tip: when you update an S\u20111 or PPM, insert a clear line stating whether the company holds qualifying state medical licences and describe the scope of covered activity. Investors want specifics, not hedged boilerplate.<\/p>\n M&A diligence now has some new, unavoidable boxes. Verify state medical licence documents, including issue and renewal dates and any OTC Therapeutic Endorsement frameworks. Sample transaction\u2011level medical\u2011purpose records to confirm the claimed covered\u2011activity percentage, because that allocation will feed both 280E relief calculations and bank\u2011compliance files.<\/p>\n Also examine whether the seller has filed any protective claims with the IRS or amended prior returns, and review the banking file for concentration, SAR histories and processor contracts. DEA registration readiness deserves its own checklist , security plans, record systems and eligibility questions are no longer theoretical.<\/p>\n This is where the market will feel it most. Historically, 280E disallowed ordinary business deductions for Schedule I activity, inflating effective federal tax rates and crushing net income. If Treasury and IRS follow through so that covered Schedule III activity escapes 280E, that recovered deductibility can expand EBITDA and lift valuations significantly , illustrative models show a possible 2\u20133x EV uplift for covered operations.<\/p>\n But don\u2019t rush to headlines. The uplift depends on: Treasury\/IRS guidance details, the company\u2019s documentation and allocation methodology, state tax interactions, and any judicial challenges to the Final Order. Disclosure must present the multiplier, the assumptions behind it, and the contingencies that could unwind the benefit.<\/p>\n FinCEN\u2019s existing marijuana\u2011related guidance and BSA obligations remain in force, so banking relationships are easier for covered activity but not guaranteed. Major card networks haven\u2019t updated their rules, meaning many operators will still lean on cash, ACH and third\u2011party processors , with the attendant operational and customer\u2011experience trade\u2011offs.<\/p>\n Separately, the Final Order contemplates an expedited DEA registration pathway for qualifying state licensees, but registration brings detailed federal controls and no promise of approval. Companies should disclose their DEA application status and readiness; lenders should tie covenants to licence and registration status where appropriate.<\/p>\n A new risk factor you must add: the Final Order itself is vulnerable to legal challenge. DOJ used treaty\u2011control authority in its approach, and plaintiffs or states could seek remand or invalidation. That uncertainty must be part of any investor communication.<\/p>\n Also remember the Schedule III benefit applies only to activity tied to qualifying state medical licences. In jurisdictions without an OTC Therapeutic Endorsement or equivalent, operators may find themselves outside the safe channel. State\u2011by\u2011state analysis and local legislative tracking are now essential for both funds and acquirers.<\/p>\n Update offering documents and LP communications immediately: fold Schedule III recognition into your investment thesis, distinguish covered versus non\u2011covered portfolio companies, and amend risk factors to reflect the eight rewrites. SPACs and public companies should expect SEC reviewers to focus on bifurcated risk and the 280E multiplier; file S\u20114, 10\u2011Ks and 8\u2011Ks with counsel and be explicit about contingent outcomes.<\/p>\n For portfolio management, consider reallocating capital toward operators with verified covered\u2011activity status or clear pathways to endorsement and DEA registration, and update valuation policies to capture the new tax dynamics.<\/p>\n It’s a small change with outsized consequences , update your disclosure and models before your next deal or filing.<\/p>\n\n
Why the Final Order rewrites investor disclosure overnight<\/h2>\n
How the eight critical risk factors should change<\/h2>\n
What lenders and buyers must add to their diligence playbooks<\/h2>\n
Tax and valuation: how the 280E multiplier changes the math<\/h2>\n
Banking, payments and DEA registration: improved but still tricky<\/h2>\n
The litigation wildcard and state dependence<\/h2>\n
What funds, SPACs and public issuers should do next<\/h2>\n
Source Reference Map<\/h3>\n